Coya Therapeutics (COYA) Stock Price, News & Analysis

Company Overview

Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors. The company employs a proprietary screening platform to identify and optimize compounds that selectively bind or inhibit UNC-45A in diseased tissues, while minimizing off-target effects in healthy cells. In addition to its internal research, Coya has established collaborations with academic and industry partners to accelerate translational studies and position its candidates for clinical entry.

Headquartered in Boston, Massachusetts, Coya Therapeutics leverages a multidisciplinary team of scientists with expertise in molecular biology, medicinal chemistry and translational medicine. The company is committed to advancing its pipeline through proof‐of‐concept studies, with the goal of delivering novel therapies that improve outcomes for patients suffering from high‐unmet‐need fibrotic and oncologic indications. Coya’s strategic focus on mechanistic innovation seeks to create durable treatment options where current standards of care are limited.

Key Stats

• Today's Range: $5.83 to $7.75
• 50-Day Range: $5.25 to $7.20
• 52-Week Range: $4.65 to $10.24
• Volume: 1.44 million shs
• Average Volume: 62,584 shs
• Market Capitalization: $120.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.20
• Consensus Rating: Moderate Buy

Coya Therapeutics Stock Analysis - MarketRank™

Coya Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 529th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Coya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Coya Therapeutics has a consensus price target of $16.20, representing about 125.0% upside from its current price of $7.20.

Amount of Analyst Coverage

Coya Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Coya Therapeutics is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Coya Therapeutics is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Coya Therapeutics has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.67% of the float of Coya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coya Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Coya Therapeutics has recently increased by 19.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Coya Therapeutics does not currently pay a dividend.

Dividend Growth

Coya Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.67% of the float of Coya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coya Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Coya Therapeutics has recently increased by 19.15%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.77

News Sentiment

Coya Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Coya Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 2 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Coya Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.00% of the stock of Coya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 39.75% of the stock of Coya Therapeutics is held by institutions.

COYA Stock Analysis - Frequently Asked Questions

How have COYA shares performed this year?

Coya Therapeutics' stock was trading at $5.73 at the start of the year. Since then, COYA stock has increased by 25.7% and is now trading at $7.20.

How were Coya Therapeutics' earnings last quarter?

Coya Therapeutics, Inc. (NASDAQ:COYA) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.14. The firm earned $0.16 million during the quarter, compared to analysts' expectations of $0.78 million.

When did Coya Therapeutics IPO?

Coya Therapeutics (COYA) raised $15 million in an initial public offering (IPO) on Thursday, December 29th 2022. The company issued 3,050,000 shares at $5.00 per share.

How do I buy shares of Coya Therapeutics?

Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Coya Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/14/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COYA
• CIK: 1835022
• Web: www.coyatherapeutics.com
• Phone: 800-587-8170
• Fax: N/A
• Employees: 6
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Coya Therapeutics: $16.20
• High Price Target: $18.00
• Low Price Target: $14.00
• Potential Upside/Downside: +125.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.88 million
• Net Margins: N/A
• Pretax Margin: -4,966.75%
• Return on Equity: -61.05%
• Return on Assets: -53.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.43
• Quick Ratio: 7.43

Sales & Book Value

• Annual Sales: $3.55 million
• Price / Sales: 33.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.37 per share
• Price / Book: 3.04

Miscellaneous

• Outstanding Shares: 16,730,000
• Free Float: 14,718,000
• Market Cap: $120.46 million
• Optionable: Not Optionable
• Beta: 0.19